NCT01554800View on ClinicalTrials.gov

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Coronary Artery DiseaseAtherosclerosis
Interventions
DRUG

ACP-501

A single dose infusion

Trial Locations (1)

20892

Cardiovascular and Pulmonary Branch (CPB) of NIH, Bethesda

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

MedImmune LLC

INDUSTRY

NCT01554800 - Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease | Biotech Hunter | Biotech Hunter